Seagen

'I don't have a checklist:' Seagen CEO talks about his next stop, Pfizer deal and the ADC landscape
'I don't have a checklist:' Seagen CEO talks about his next stop, Pfizer deal and the ADC landscape
Fierce Pharma
Seagen
Pharma CEOs
David Epstein
Pfizer
Flag link:
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
Motley Fool
FTC
M&A
Amgen
Horizon Therapeutics
Pfizer
Seagen
Flag link:
Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News
Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News
Motley Fool
Pfizer
debt
Seagen
M&A
Flag link:
Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say
Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say
Fierce Pharma
FTC
M&A
Amgen
Horizon Therapeutics
Pfizer
Seagen
antitrust
Flag link:
Heightened US antitrust fears rattle biopharma
Heightened US antitrust fears rattle biopharma
EP Vantage
M&A
antitrust
Amgen
Astellas
Bellus Health
Globus Medical
GSK
Horizon Therapeutics
Merck
NuVasive
Pfizer
Prometheus Biosciences
Seagen
Flag link:
Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board?
Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board?
Fierce Pharma
Pfizer
Seagen
M&A
antitrust
DOJ
FTC
Flag link:
Biopharma Bets Big on Antibody-Drug Conjugates
Biopharma Bets Big on Antibody-Drug Conjugates
BioSpace
antibody-drug conjugate
Merck
Seagen
M&A
AstraZeneca
BioNTech
Bristol Myers Squibb
Flag link:
In Pfizer's $43B acquisition of Seagen, the biotech's patience paid off
In Pfizer's $43B acquisition of Seagen, the biotech's patience paid off
Fierce Pharma
Pfizer
Seagen
M&A
Merck
Flag link:
Pfizer's fortunes overshadow first-quarter dealmaking
Pfizer's fortunes overshadow first-quarter dealmaking
EP Vantage
M&A
Pfizer
Seagen
Sanofi
Provention Bio
AstraZeneca
CinCor
Chiesi
Amryt
Ipsen
Albireo
Flag link:
Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?
Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?
Fierce Pharma
M&A
antitrust
FTC
Sanofi
Provention Bio
Pfizer
Seagen
Flag link:
Biopharma stocks go back to bleak
Biopharma stocks go back to bleak
EP Vantage
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
Flag link:
FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer
FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer
BioSpace
Merck
Seagen
Astellas
Keytruda
Padcev
metastatic urothelial carcinoma
FDA
Flag link:
Disgraced former Seagen CEO tapped to lead MorphImmune less than a year after domestic assault arrest
Disgraced former Seagen CEO tapped to lead MorphImmune less than a year after domestic assault arrest
Fierce Biotech
Seagen
MorphImmunce
Pharma CEOs
Purdue University
Clay Siegall
Flag link:
In Pfizer-Seagen review, FTC has chance to set new pharma precedent
In Pfizer-Seagen review, FTC has chance to set new pharma precedent
BioPharma Dive
FTC
Pfizer
Seagen
M&A
antitrust
anticompetitive practices
Flag link:
Pfizer CEO points to IRA as a factor that made Seagen an attractive target
Pfizer CEO points to IRA as a factor that made Seagen an attractive target
Endpoints
Pfizer
Seagen
M&A
Inflation Reduction Act
Flag link:
Pfizer to buy Seagen in $43B cancer drug deal
Pfizer to buy Seagen in $43B cancer drug deal
BioPharma Dive
Pfizer
Seagen
M&A
lymphoma
Adcetris
Flag link:
Pfizer Is Targeting an Acquisition That Could Be a Game Changer for Its Business
Pfizer Is Targeting an Acquisition That Could Be a Game Changer for Its Business
Motley Fool
Pfizer
Seagen
M&A
Flag link:
Seagen has a New Suitor as Pfizer Talks Begin
Seagen has a New Suitor as Pfizer Talks Begin
BioSpace
Seagen
Pfizer
M&A
Flag link:
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Endpoints
Daiichi Sankyo
Seagen
PTO
patents
Flag link:
Seagen mum on Merck buyout rumors as it bats for blockbuster with Adcetris
Seagen mum on Merck buyout rumors as it bats for blockbuster with Adcetris
BioSpace
Seagen
earnings
Merck
M&A
Adcetris
Flag link:

Pages